EHRA Premium Access

Machine-learned physiological signatures from the ECG predict sudden death in ischemic cardiomyopathy

Congress Session

About the speaker

Mr Samuel Ruiperez-Campillo

Stanford University School of Medicine, Palo Alto (United States of America)
0 follower

6 more presentations in this session

A novel weighted hybrid clinical and electrocardiographic score to predict the origin of outflow tract ventricular arrhythmias: a multicenter study.

Speaker: Doctor G. Falasconi (Barcelona, ES)

Thumbnail

QT interval prolongation is a novel predictor of one year morality in patients with coronavirus disease-19 infection

Speaker: Doctor A. Banai (Tel Aviv, IL)

Thumbnail

Incidental arrhythmias during atrial fibrillation screening in a hospital-based patient population

Speaker: Doctor E. Goulouti (Bern, CH)

Thumbnail

Novel CineECG to identify disease onset and progression in pathogenic plakophilin-2 mutation carriers

Speaker: Miss M. Boonstra (Utrecht, NL)

Thumbnail

Endocardial and epicardial ECG imaging during sinus rhythm to detect local conduction delay in arrhythmogenic cardiomyopathy

Speaker: Miss M. Boonstra (Utrecht, NL)

Thumbnail

Access the full session

Moderated ePosters - Diagnostic methods to improve arrhythmia therapy

Speakers: Mr S. Ruiperez-Campillo, Doctor G. Falasconi, Doctor A. Banai, Doctor E. Goulouti, Miss M. Boonstra...
Thumbnail

About the event

Image

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Related content

EHRA Premium Access

Pulsed field ablation of atrial fibrillation: recurrence rate after first pulmonary vein isolation and first insights into durability at redo procedures

3 April 2022

EHRA Premium Access

Selective epicardial pulsed field ablation of atrial ganglionated plexi causes anti-arrhythmic prolongation of refractoriness: demonstration of feasibility in cardiac surgery patients

3 April 2022

Open Access

SGLT-2 Inhibitors in Heart Failure: Where are we now and where are we heading?

27 August 2021

This platform is supported by

logo Novo Nordisk